Enzon Pharmaceuticals, Inc. (Bridgewater, New Jersey)
Corporate Headquarters
685 Route 202/206
Bridgewater
New Jersey
08807
United States
Tel: 908-541-8600
Fax: 908-575-9457
Website: http://www.enzon.com/
175 articles about Enzon Pharmaceuticals, Inc. (Bridgewater, New Jersey)
-
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
-
The U.S. FDA had a very packed calendar for this week, but almost everything on it was under a Priority Review pathway.
-
Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon’s CFO, to Assume Position of CEO and Remain CFO
1/4/2021
Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Company’s Chief Executive Officer effective February 26, 2021. Andy joined Enzon in 2010 as Vice-President and General Counsel and has served as CEO since 2016. Upon Andy’s retirement, Richard L. Feinstein, Enzon’s Chief Financial Officer, will also assume the role of Chief Executive Officer and Secr
-
Enzon Pharmaceuticals Announces Key Dates for Rights Offering
9/15/2020
Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its previously-announced rights offering to raise proceeds of approximately $43 million. The proceeds from the rights offering will be utilized to position the Company as a public company acquisition vehicle, where it can become an acquisition platform and more fully utilize its net operating loss tax carryfor
-
Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting
9/2/2020
Enzon Pharmaceuticals, Inc. announced that its 2020 annual meeting of stockholders originally scheduled to be held on Thursday, September 17, 2020, has been postponed and will now be held on Friday, December 18, 2020.
-
Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders
8/21/2020
Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved a rights offering to existing shareholders whereby the Company intends to distribute one transferable subscription right for each outstanding share of common stock owned.
-
Enzon Pharmaceuticals, Inc. Adopts Stockholder Rights Plan In An Effort To Protect Net Operating Loss Carryforwards
5/2/2014
-
Santaris Pharma A/S Resumes Full Ownership of Cancer Programs Licensed to Enzon Pharmaceuticals, Inc.
10/28/2013
-
Enzon Pharmaceuticals, Inc. Concludes Review of Possible Asset Sales, Sale of the Company; Announces $1.60 Special Dividend and Periodic Royalty Dividends
4/24/2013
-
Enzon Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2012 Results
3/19/2013
-
Legendary Icahn Still Slugging Away With Enzon Pharmaceuticals, Inc.
1/8/2013
-
Enzon Pharmaceuticals, Inc. to Trim Workforce by About Half, to Stop Drug Development
12/26/2012
-
Enzon Pharmaceuticals, Inc. to Explore Sale of Company After Icahn Wants Talk
12/17/2012
-
Enzon Pharmaceuticals (Piscataway, New Jersey) Announces Special Dividend
11/30/2012
-
Enzon Pharmaceuticals, Inc. Reports Third Quarter 2012 Results
10/31/2012
-
Enzon Pharmaceuticals, Inc. to Present at 2012 World Congress and Expo on Biowaivers and Biosimilars
9/11/2012
-
Enzon Pharmaceuticals (Piscataway, New Jersey) Reports Second Quarter 2012 Results
8/1/2012
-
Enzon Pharmaceuticals, Inc. Presents Pre-Clinical Data on Controlled Release of PEGylated Interferon-Beta-1b and PEGylated anti-TNF-a Antibody Fragment at the Controlled Release Society Annual Meeting
7/16/2012
-
Enzon Pharmaceuticals (Piscataway, New Jersey) Announces Data From Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference
6/19/2012
-
Enzon Pharmaceuticals, Inc. Presents Final Analysis of Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer at 2012 American Society of Clinical Oncology Meeting
6/5/2012